NCT00567112View on ClinicalTrials.gov

Study to Evaluate the Pharmacokinetics & Food Effect of MK-0941 in Adults With Type 2 Diabetes (MK-0941-009)

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

February 29, 2008

Study Completion Date

April 30, 2008

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

10 mg MK-0941 DFC (fasted)

single dose of 10 mg MK-0941 dry filled capsules (DFC) administered in a fasted state

DRUG

10 mg MK-0941 OCT (after meal)

single dose of 10 mg MK-0941 oral compressed tablet (OCT) administered after consumption of a high-fat meal

DRUG

10 mg MK-0941 OCT (before meal)

single dose of 10 mg MK-0941 oral compressed tablet (OCT) administered before consumption of a standard breakfast

DRUG

10 mg MK-0941 OCT (fasted)

single dose of 10 mg MK-0941 oral compressed tablet (OCT) administered in a fasted state

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00567112 - Study to Evaluate the Pharmacokinetics & Food Effect of MK-0941 in Adults With Type 2 Diabetes (MK-0941-009) | Biotech Hunter | Biotech Hunter